Patents by Inventor Chikafumi OZONE
Chikafumi OZONE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220364054Abstract: The present invention provides a method for producing a retinal progenitor cell, including (1) a first step of subjecting pluripotent stem cells to floating culture in a serum-free medium to form an aggregate of pluripotent stem cells, and (2) a second step of subjecting the aggregate formed in step (1) to floating culture in a serum-free medium or serum-containing medium each being free of a substance acting on the Sonic hedgehog signal transduction pathway but containing a substance acting on the BMP signal transduction pathway, thereby obtaining an aggregate containing retinal progenitor cells.Type: ApplicationFiled: July 21, 2022Publication date: November 17, 2022Applicants: SUMITOMO CHEMICAL COMPANY, LIMITED, RIKENInventors: Tokushige NAKANO, Yoshiki SASAI, Chikafumi OZONE
-
Patent number: 11473056Abstract: The present invention provides a method for producing a retinal progenitor cell, including (1) a first step of subjecting pluripotent stem cells to floating culture in a serum-free medium to form an aggregate of pluripotent stem cells, and (2) a second step of subjecting the aggregate formed in step (1) to floating culture in a serum-free medium or serum-containing medium each being free of a substance acting on the Sonic hedgehog signal transduction pathway but containing a substance acting on the BMP signal transduction pathway, thereby obtaining an aggregate containing retinal progenitor cells.Type: GrantFiled: November 22, 2019Date of Patent: October 18, 2022Assignees: SUMITOMO CHEMICAL COMPANY, LIMITED, RIKENInventors: Tokushige Nakano, Yoshiki Sasai, Chikafumi Ozone
-
Patent number: 11274277Abstract: The present invention provides a production method of a cell aggregate containing an anterior eye segment tissue or a partial structure thereof, or a precursor tissue thereof, including culturing pluripotent stem cell aggregates in suspension in the presence of a bone morphogenic factor signal transduction pathway activating substance to induce self-organization of an anterior eye segment tissue or a partial structure thereof, or a precursor tissue thereof. In one embodiment, the bone morphogenic factor signal transduction pathway activating substance is BMP4. In one embodiment, the suspension culture is performed entirely or partially in the presence of a fibroblast growth factor. The produced cell aggregate can further contain a neural retinal tissue.Type: GrantFiled: August 6, 2014Date of Patent: March 15, 2022Assignees: RIKEN, Sumitomo Chemical Company, LimitedInventors: Yoshiki Sasai, Chikafumi Ozone, Yuko Maruyama
-
Publication number: 20200370010Abstract: The invention provides a method for inducing adenohypophysis or precursor tissue thereof in vitro from human pluripotent stem cells. The method includes culturing an aggregate of human pluripotent stem cells in suspension in a medium containing a bone morphogenetic protein signal transduction pathway activating substance and a substance acting on the Shh signal pathway to obtain a human cell aggregate containing a hypothalamus neuroepithelial tissue and a surface ectoderm, and further culturing the obtained human cell aggregate containing the hypothalamus neuroepithelial tissue and the surface ectoderm in suspension in a medium containing a bone morphogenetic protein signal transduction pathway activating substance and a substance acting on the Shh signal pathway to induce formation of hypophysial placode and/or Rathke's pouch in the surface ectoderm, thus obtaining a human cell aggregate containing 1) hypothalamus neuroepithelial tissue, and 2) hypophysial placode and/or Rathke's pouch.Type: ApplicationFiled: August 12, 2020Publication date: November 26, 2020Applicants: RIKEN, SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: Yoshiki Sasai (deceased), Chikafumi OZONE, Hidetaka SUGA
-
Patent number: 10760050Abstract: The present invention provides a method for producing a retinal pigment epithelial cell, including (1) a first step of subjecting pluripotent stem cells to floating culture in a serum-free medium to form an aggregate of pluripotent stem cells, (2) a second step of subjecting the aggregate formed in step (1) to floating culture in a serum-free medium or serum-containing medium each being free of a substance acting on the Sonic hedgehog signal transduction pathway and containing a substance acting on the BMP signal transduction pathway, thereby obtaining an aggregate containing retinal progenitor cells, and (3) a third step of subjecting the aggregate formed in step (2) to floating culture in a serum-free medium or serum-containing medium each being free of a substance acting on the Sonic hedgehog signal transduction pathway and a substance acting on the BMP signal transduction pathway and containing a substance acting on the Wnt signal pathway, thereby obtaining an aggregate containing retinal pigment epithelType: GrantFiled: October 2, 2014Date of Patent: September 1, 2020Assignees: SUMITOMO CHEMICAL COMPANY, LIMITED, RIKENInventors: Tokushige Nakano, Yoshiki Sasai, Chikafumi Ozone
-
Patent number: 10760047Abstract: The present invention provides a method for inducing adenohypophysis or precursor tissue thereof in vitro from human pluripotent stem cells. The method includes culturing an aggregate of human pluripotent stem cells in suspension in a medium containing a bone morphogenetic protein signal transduction pathway activating substance and a substance acting on the Shh signal pathway to obtain a human cell aggregate containing a hypothalamus neuroepithelial tissue and a surface ectoderm, and further culturing the obtained human cell aggregate containing the hypothalamus neuroepithelial tissue and the surface ectoderm in suspension in a medium containing a bone morphogenetic protein signal transduction pathway activating substance and a substance acting on the Shh signal pathway to induce formation of hypophysial placode and/or Rathke's pouch in the surface ectoderm, thus obtaining a human cell aggregate containing 1) hypothalamus neuroepithelial tissue, and 2) hypophysial placode and/or Rathke's pouch.Type: GrantFiled: July 24, 2015Date of Patent: September 1, 2020Assignees: RIKEN, SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: Yoshiki Sasai, Chikafumi Ozone, Hidetaka Suga
-
Publication number: 20200102535Abstract: The present invention provides a method for producing a retinal progenitor cell, including (1) a first step of subjecting pluripotent stem cells to floating culture in a serum-free medium to form an aggregate of pluripotent stem cells, and (2) a second step of subjecting the aggregate formed in step (1) to floating culture in a serum-free medium or serum-containing medium each being free of a substance acting on the Sonic hedgehog signal transduction pathway but containing a substance acting on the BMP signal transduction pathway, thereby obtaining an aggregate containing retinal progenitor cells.Type: ApplicationFiled: November 22, 2019Publication date: April 2, 2020Applicants: SUMITOMO CHEMICAL COMPANY, LIMITED, RIKENInventors: Tokushige NAKANO, Yoshiki SASAI, Chikafumi OZONE
-
Patent number: 10501724Abstract: The present invention provides a method for producing a retinal progenitor cell, including (1) a first step of subjecting pluripotent stem cells to floating culture in a serum-free medium to form an aggregate of pluripotent stem cells, and (2) a second step of subjecting the aggregate formed in step (1) to floating culture in a serum-free medium or serum-containing medium each being free of a substance acting on the Sonic hedgehog signal transduction pathway but containing a substance acting on the BMP signal transduction pathway, thereby obtaining an aggregate containing retinal progenitor cells.Type: GrantFiled: August 22, 2014Date of Patent: December 10, 2019Assignees: SUMITOMO CHEMICAL COMPANY, LIMITED, RIKENInventors: Tokushige Nakano, Yoshiki Sasai, Chikafumi Ozone
-
Publication number: 20180195041Abstract: The present invention provides a method for inducing adenohypophysis or precursor tissue thereof in vitro from human pluripotent stem cells. The method includes culturing an aggregate of human pluripotent stem cells in suspension in a medium containing a bone morphogenetic protein signal transduction pathway activating substance and a substance acting on the Shh signal pathway to obtain a human cell aggregate containing a hypothalamus neuroepithelial tissue and a surface ectoderm, and further culturing the obtained human cell aggregate containing the hypothalamus neuroepithelial tissue and the surface ectoderm in suspension in a medium containing a bone morphogenetic protein signal transduction pathway activating substance and a substance acting on the Shh signal pathway to induce formation of hypophysial placode and/or Rathke's pouch in the surface ectoderm, thus obtaining a human cell aggregate containing 1) hypothalamus neuroepithelial tissue, and 2) hypophysial placode and/or Rathke's pouch.Type: ApplicationFiled: July 24, 2015Publication date: July 12, 2018Applicants: RIKEN, SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: Yoshiki Sasai, Chikafumi OZONE, Hidetaka SUGA
-
Publication number: 20160264936Abstract: The present invention provides a method for producing a retinal pigment epithelial cell, including (1) a first step of subjecting pluripotent stem cells to floating culture in a serum-free medium to form an aggregate of pluripotent stem cells, (2) a second step of subjecting the aggregate formed in step (1) to floating culture in a serum-free medium or serum-containing medium each being free of a substance acting on the Sonic hedgehog signal transduction pathway and containing a substance acting on the BMP signal transduction pathway, thereby obtaining an aggregate containing retinal progenitor cells, and (3) a third step of subjecting the aggregate formed in step (2) to floating culture in a serum-free medium or serum-containing medium each being free of a substance acting on the Sonic hedgehog signal transduction pathway and a substance acting on the BMP signal transduction pathway and containing a substance acting on the Wnt signal pathway, thereby obtaining an aggregate containing retinal pigment epithelType: ApplicationFiled: October 2, 2014Publication date: September 15, 2016Applicants: SUMITOMO CHEMICAL COMPANY, LIMITED, RIKENInventors: Tokushige NAKANO, Yoshiki SASAI, Chikafumi OZONE
-
Publication number: 20160251616Abstract: The present invention provides a method for producing a retinal progenitor cell, including (1) a first step of subjecting pluripotent stem cells to floating culture in a serum-free medium to form an aggregate of pluripotent stem cells, and (2) a second step of subjecting the aggregate formed in step (1) to floating culture in a serum-free medium or serum-containing medium each being free of a substance acting on the Sonic hedgehog signal transduction pathway but containing a substance acting on the BMP signal transduction pathway, thereby obtaining an aggregate containing retinal progenitor cells.Type: ApplicationFiled: August 22, 2014Publication date: September 1, 2016Applicants: SUMITOMO CHEMICAL COMPANY, LIMITED, RIKENInventors: Tokushige NAKANO, Yoshiki SASAI, Chikafumi OZONE
-
Publication number: 20160186136Abstract: The present invention provides a production method of a cell aggregate containing an anterior eye segment tissue or a partial structure thereof, or a precursor tissue thereof, including culturing pluripotent stem cell aggregates in suspension in the presence of a bone morphogenic factor signal transduction pathway activating substance to induce self-organization of an anterior eye segment tissue or a partial structure thereof, or a precursor tissue thereof. In one embodiment, the bone morphogenic factor signal transduction pathway activating substance is BMP4. In one embodiment, the suspension culture is performed entirely or partially in the presence of a fibroblast growth factor. The produced cell aggregate can further contain a neural retinal tissue.Type: ApplicationFiled: August 6, 2014Publication date: June 30, 2016Applicant: RIKENInventors: Yoshiki SASAI (deceased), Miyuki SASAI (Legal Representive), Chikafumi OZONE, Yuko MARUYAMA